These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11400666)

  • 21. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
    Bowman MJ; Chmielewski J
    Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A fast and robust 19F NMR-based method for finding new HIV-1 protease inhibitors.
    Frutos S; Tarrago T; Giralt E
    Bioorg Med Chem Lett; 2006 May; 16(10):2677-81. PubMed ID: 16517158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing drugs against heterogeneous targets.
    Freire E
    Nat Biotechnol; 2002 Jan; 20(1):15-6. PubMed ID: 11753347
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of HIV-1 protease inhibitor resistance by Molecular Modeling Protocols (MMPs) using GenMol software.
    Pèpe G; Courcambeck J; Perbost R; Jouanna P; Halfon P
    Eur J Med Chem; 2008 Nov; 43(11):2518-34. PubMed ID: 18455274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
    Li D; Liu MS; Ji B; Hwang K; Huang Y
    J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteases and protease inhibitors.
    Van Noorden CJ
    Acta Histochem; 1997 Aug; 99(3):245-7. PubMed ID: 9381907
    [No Abstract]   [Full Text] [Related]  

  • 30. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
    Garg R; Patel D
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3767-70. PubMed ID: 15993582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
    Tamiya S; Mardy S; Kavlick MF; Yoshimura K; Mistuya H
    J Virol; 2004 Nov; 78(21):12030-40. PubMed ID: 15479842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
    Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
    J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consensus statement on the further development of protease inhibitors and human growth hormone.
    AIDS Treat News; 1996 Mar; (no 243):8. PubMed ID: 11363302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
    Ode H; Neya S; Hata M; Sugiura W; Hoshino T
    J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
    Meagher KL; Carlson HA
    J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
    Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
    J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.